Archived explainer. For the current picture see today's ARWR page.
ARROWHEAD PHARMACEUT (ARWR) is up +19.03% in the latest session. Our newswire has captured 13 stories on ARWR across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 71/100).
Arrowhead Pharmaceuticals stock surged nearly 19% to $88.70 on Monday, marking its best one-day gain in nearly eight months. The rally was driven by positive Phase 3 trial results for its lipid-lowering drug plozasiran and an analyst upgrade from Chardan Capital. The stock closed at a 52-week high, reflecting renewed investor confidence in the company's pipeline and potential for broader FDA approval.
Arrowhead announced positive topline results from two Phase 3 studies evaluating plozasiran for the treatment of hypertriglyceridemia. The results showed significant reductions in triglyceride levels, with one trial achieving 79-81% reductions. These findings were described as a "derisking event" by analysts, reducing regulatory and commercial uncertainties. Chardan analyst Keay Nakae raised the firm's price target on Arrowhead to $115 from $90 and maintained a Buy rating. The analyst cited the strong data and the company's competitive position against peers like Ionis as key catalysts. The stock's surge also coincided with a webcast scheduled for August 4, 2026, where the company will provide further insights into its pipeline and strategic direction.
The stock's intraday movement showed a sharp upward trend, closing near the session high. The move pushed Arrowhead to a 52-week high of $88.70, just above its previous peak of $87.83. The company's market cap now stands at $10.5 billion, despite remaining unprofitable with a trailing twelve-month EPS of -2.17. Revenue has grown by 14.1% TTM, but the net margin remains negative at -48.4%. Unusual options activity included a notable put premium of $560K, indicating some bearish positioning. Recent insider transactions show one director sold $228K in shares, while a major congressional trade reported a sale of $100,001-$250,000.
Investors should monitor the scheduled webcast on August 4, 2026, for further updates on Arrowhead's pipeline and strategic direction. The company's upcoming regulatory filings and any additional Phase 3 data will be key to sustaining the recent momentum.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Chardan analyst Keay Nakae raised the firm's price target on Arrowhead to $115 from $90 and keeps a Buy rating on the shares.
Arrowhead Pharmaceuticals, Inc. jumped on Phase 3 plozasiran sHTG data; see key catalysts, risks, and upside vs Ionis ahead of filings. Click for this ARWR update.
Arrowhead Pharmaceuticals (ARWR) stock hits a 52-week high as analysts cheer a late-stage trial win for the company's lipid-lowering drug plozasiran. Read more here.
Arrowhead Pharmaceuticals stock saw major gains after the company announced new results from a Phase 3 trial.
Arrowhead Pharmaceuticals will hold a webcast for its fiscal 2026 third quarter results on August 4, 2026. The announcement comes as Arrowhead’s pipeline continues to draw attention, with investors keen on insights into its RNAi platform and upcoming milestones.
Arrowhead Pharmaceuticals reported positive phase 3 results for Redemplo, achieving 79-81% triglyceride reductions. Click here to read an analysis of ARWR stock now.
The biotech firm reported positive topline results from two Phase 3 studies evaluating its hypertriglyceridemia therapy.
More on ARWR: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ARWR move explainers: 2026-07-23 · 2026-07-22